847 related articles for article (PubMed ID: 17001014)
21. The nuclear chaperone nucleophosmin escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells.
Liu CD; Chen YL; Min YL; Zhao B; Cheng CP; Kang MS; Chiu SJ; Kieff E; Peng CW
PLoS Pathog; 2012; 8(12):e1003084. PubMed ID: 23271972
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells.
Deacon EM; Pallesen G; Niedobitek G; Crocker J; Brooks L; Rickinson AB; Young LS
J Exp Med; 1993 Feb; 177(2):339-49. PubMed ID: 8381153
[TBL] [Abstract][Full Text] [Related]
23. Parallel existence of Epstein-Barr virus (EBV) positive and negative cells in a sporadic case of Burkitt lymphoma.
Trivedi P; Zhang QJ; Chen F; Minarovits J; Ekman M; Biberfeld P; Klein G; Winberg G
Oncogene; 1995 Aug; 11(3):505-10. PubMed ID: 7630634
[TBL] [Abstract][Full Text] [Related]
24. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
[TBL] [Abstract][Full Text] [Related]
25. EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma.
Ruf IK; Rhyne PW; Yang H; Borza CM; Hutt-Fletcher LM; Cleveland JL; Sample JT
Curr Top Microbiol Immunol; 2001; 258():153-60. PubMed ID: 11443860
[No Abstract] [Full Text] [Related]
26. Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma.
Ruf IK; Rhyne PW; Yang H; Borza CM; Hutt-Fletcher LM; Cleveland JL; Sample JT
Mol Cell Biol; 1999 Mar; 19(3):1651-60. PubMed ID: 10022853
[TBL] [Abstract][Full Text] [Related]
27. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease.
Chiang AK; Tao Q; Srivastava G; Ho FC
Int J Cancer; 1996 Nov; 68(3):285-90. PubMed ID: 8903467
[TBL] [Abstract][Full Text] [Related]
28. Identification of Host Biomarkers of Epstein-Barr Virus Latency IIb and Latency III.
Messinger JE; Dai J; Stanland LJ; Price AM; Luftig MA
mBio; 2019 Jul; 10(4):. PubMed ID: 31266868
[TBL] [Abstract][Full Text] [Related]
29. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
Gregory CD; Rowe M; Rickinson AB
J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
[TBL] [Abstract][Full Text] [Related]
30. EBNA promoter usage in EBV-negative Burkitt lymphoma cell lines converted with a neomycin-resistant EBV strain.
Maeda A; Kiss C; Chen F; Ehlin-Henriksson B; Nagy N; Szekely L; Takada K; Klein E; Klein G
Int J Cancer; 2001 Sep; 93(5):714-9. PubMed ID: 11477584
[TBL] [Abstract][Full Text] [Related]
31. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines.
Floettmann JE; Ward K; Rickinson AB; Rowe M
Virology; 1996 Sep; 223(1):29-40. PubMed ID: 8806537
[TBL] [Abstract][Full Text] [Related]
32. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMP1, and its expression promotes the survival of a Burkitt's lymphoma cell line.
D'Souza B; Rowe M; Walls D
J Virol; 2000 Jul; 74(14):6652-8. PubMed ID: 10864681
[TBL] [Abstract][Full Text] [Related]
33. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
Kis LL; Takahara M; Nagy N; Klein G; Klein E
Immunol Lett; 2006 Apr; 104(1-2):83-8. PubMed ID: 16386314
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency.
Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G
Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
Tierney RJ; Steven N; Young LS; Rickinson AB
J Virol; 1994 Nov; 68(11):7374-85. PubMed ID: 7933121
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.
Pegman PM; Smith SM; D'Souza BN; Loughran ST; Maier S; Kempkes B; Cahill PA; Simmons MJ; Gélinas C; Walls D
J Virol; 2006 Aug; 80(16):8133-44. PubMed ID: 16873269
[TBL] [Abstract][Full Text] [Related]
37. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
Perez-Chacon G; de Los Rios C; Zapata JM
Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
[TBL] [Abstract][Full Text] [Related]
38. The NP9 protein encoded by the human endogenous retrovirus HERV-K(HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2).
Gross H; Barth S; Pfuhl T; Willnecker V; Spurk A; Gurtsevitch V; Sauter M; Hu B; Noessner E; Mueller-Lantzsch N; Kremmer E; Grässer FA
Int J Cancer; 2011 Sep; 129(5):1105-15. PubMed ID: 21710493
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr Virus B Cell Growth Transformation: The Nuclear Events.
Zhao B
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112815
[TBL] [Abstract][Full Text] [Related]
40. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]